title: Optic neuritis due to immunobiologics: first Brazilian case report.
abstract: The change in immunological response obtained by immunobiologics has brought a new paradigm to the treatment of immune-mediated disorders. As a result of their efficacy, there is a positive impact on the quality of life of patients. However, severe side effects, such as demyelination of cerebral or peripheral nerves, have been reported. After review of literature using PubMed and MEDLINE data from 2000 to 2012, we identified the cases correlating the biological uniterms and optic neuritis. This article reports the first Brazilian optic neuritis case associated with the use of immunobiologics. This publication is justified by the rarity of the disease and atypical therapeutical evolution.
authors.affiliation: Universidade do Oeste Paulista, Presidente Prudente Regional Hospital, Dermatology Service, Presidente PrudenteSP, Brazil.
authors.forename: Luiz Gustavo Martins da
authors.initials: LG
authors.lastname: Silva
authors.affiliation: Universidade do Oeste Paulista, Presidente Prudente Regional Hospital, Ophthalmology Service, Presidente PrudenteSP, Brazil.
authors.forename: Letícia Soares
authors.initials: LS
authors.lastname: Sasso
authors.affiliation: Universidade do Oeste Paulista, Presidente Prudente Regional Hospital, Dermatology Service, Presidente PrudenteSP, Brazil.
authors.forename: Carlos José
authors.initials: CJ
authors.lastname: Nelli
authors.affiliation: Rio de Janeiro Santa Casa da MisericórdiaProfessor Rubem David Azulay Institute of DermatologyHospital, Rio de JaneiroRJ, Brazil.
authors.forename: Fred
authors.initials: F
authors.lastname: Bernardes Filho
authors.affiliation: Dermatology Service, Presidente Prudente Regional Hospital, Universidade do Oeste Paulista, Rio de JaneiroRJ, Brazil.
authors.forename: Marilda Aparecida Milanez Morgado de
authors.initials: MA
authors.lastname: Abreu
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D001938:Brazil; D003879:Dermatologic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009902:Optic Neuritis / Q000139:chemically induced*; D011565:Psoriasis / Q000188:drug therapy*; D014792:Visual Acuity; D058609:Visual Field Tests
chemical_list: D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab